Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-4 (of 4 Records) |
Query Trace: Willoughby RE Jr[original query] |
---|
Overcoming barriers to low hpv vaccine uptake in the United States: Recommendations from the national vaccine advisory committee
Orenstein WA , Gellin BG , Beigi RH , Despres S , Lynfield R , Maldonado Y , Mouton C , Rawlins W , Rothholz MC , Smith N , Thompson K , Torres C , Viswanath K , Hosbach P , Despres S , Rawlins W , Orenstein WA , Beigi RH , Hosbach P , Rothholz MC , Viswanath K , Bobo N , Brewer NT , Eckert L , Etkind P , Kahn JA , Loehr J , Martin K , Morita J , Salisbury D , Saslow D , Tan L , Turner JC , Willoughby RE Jr , Borden V , Croyle R , Deal CD , Gold R , Hance MBE , Hess MA , Lee NC , Lowy D , Stokley S , Wharton M , Bergquist S , Bok K , Gellin BG , Seib K , Zettle M . Public Health Rep 2016 131 (1) 17-25 An average of 25,900 cases of human papillomavirus (HPV)-associated cancers are newly diagnosed in the United States each year.1,2 An estimated 14 million people are newly infected with HPV each year, and nearly half of these infections occur in people aged 14–25 years.3 Although most infections resolve over time, persistent infection with oncogenic HPV types is associated with a variety of cancers. Virtually all cervical cancers are caused by HPV, along with 90% of anal, 69% of vaginal, 60% of oropharyngeal, 51% of vulvar, and 40% of penile cancers.1 Furthermore, 87% of anal, 76% of cervical, 60% of oropharyngeal, 55% of vaginal, 44% of vulva, and 29% of penile cancers are caused by oncogenic HPV type 16 or 18.4 Of the 35,000 HPV cancers reported in 2009 in the United States, 39% occurred in males.1 | Three HPV vaccines are currently available in the United States. One is a bivalent vaccine (designated as HPV2) designed to protect against HPV types 16 and 18, which are responsible for the most HPV-associated cancers. One is a quadrivalent vaccine (HPV4), which protects against HPV types 16 and 18 and two additional types, 6 and 11, that are the most common causes of genital warts. One is a nonavalent vaccine (HPV9) that protects against HPV types 6, 11, 16, and 18, and offers additional protection against five oncogenic HPV types, 31, 33, 45, 52, and 58. To prevent cancers associated with HPV infections, the Advisory Committee on Immunization Practices (ACIP) recommends HPV immunization for all children aged 11 or 12 years with the licensed three-doses series. The ACIP has recommended routine HPV immunization for girls since 2006 and for boys since 2011.2 |
Virology, immunology and pathology of human rabies during treatment.
Caicedo Y , Paez A , Kuzmin I , Niezgoda M , Orciari LA , Yager PA , Recuenco S , Franka R , Velasco-Villa A , Willoughby RE Jr . Pediatr Infect Dis J 2014 34 (5) 520-8 BACKGROUND: Rabies is an acute fatal encephalitis caused by all members of the Lyssavirus genus. The first human rabies survivor without benefit of prior vaccination was reported from Milwaukee in 2005. We report a second unvaccinated patient who showed early recovery from rabies and then died accidentally during convalescence, providing an unparalleled opportunity to examine the histopathology as well as immune and virological correlates of early recovery from human rabies. METHODS: Case report, rapid fluorescent focus inhibition test, enzyme-linked immunosorbent assay, indirect and direct fluorescent antibody assays, reverse-transcriptase polymerase chain reaction, phylogenetic reconstruction, isolation in tissue culture, pathology and immunohistochemistry. RESULTS: The 9 year old died 76 days after presenting with rabies of vampire bat phylogeny transmitted by cat bite. Antibody response in serum and CSF was robust and associated with severe cerebral edema. No rabies virus was cultured at autopsy. Rabies virus antigen was atypical in size and distribution. Rabies virus genome was present in neocortex but absent in brainstem. CONCLUSIONS:: Clinical recovery was associated with detection of neutralizing antibody and clearance of infectious rabies virus in the CNS by 76 days, but not clearance of detectable viral subcomponents such as nucleoprotein antigen or RNA in brain. |
Policy statement--Recommended childhood and adolescent immunization schedules--United States, 2010
Bocchini JA Jr , Bradley JS , Brady MT , Bernstein HH , Byington CL , Fisher MC , Glode MP , Jackson MA , Keyserling HL , Kimberlin DW , Orenstein WA , Schutze GE , Willoughby RE Jr , Bell BP , Bortolussi R , Clover RD , Fischer MA , Gorman RL , Lee L , Pratt RD , Read JS , Gellin BG , Starke JR , Swanson J , Meissner HC , Rubin LG , Pickering LK , Baker CJ , Long SS , Frantz J , Committee on Infectious Diseases . Pediatrics 2010 125 (1) 195-6 The 2010 recommended childhood and adolescent immunization schedules have been approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, and the American Academy of Family Physicians. There are 3 schedules: one for children 0 through 6 years of age, one for people 7 through 18 years of age, and a catch-up immunization schedule for children and adolescents who start late or fall behind. These schedules reflect current recommendations for the use of vaccines licensed by the US Food and Drug Administration and include the following changes from last year: | Reference to the recommendations of the Advisory Committee on Immunization Practices for use of influenza A (H1N1) 2009 monovalent vaccine1 is included in a footnote. | Revaccination with meningococcal conjugate vaccine (MCV4) is recommended for children who remain at increased risk for meningococcal disease. A dose of MCV4 should be administered after 3 years in children who received the initial MCV4 dose at ages 2 through 6 years and after 5 years if the first dose was given at age 7 years or older. Additional doses of MCV4 are then given every 5 years.2 | Recommendations on use of combination vaccines have been updated (the use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines). The final dose in the inactivated poliovirus vaccine series should be administered on or after the 4th birthday and at least 6 months following the previous dose. If 4 doses are administered before age 4 years, an additional (fifth) dose should be administered at age 4 through 6 years.3 | Recommendations for use of the recently licensed bivalent human papillomavirus vaccine in females and the quadrivalent human papillomavirus vaccine in males are included. | Most of the footnotes for the individual vaccines have been revised to provide additional information and to clarify recommendations provided in the schedules. |
Applying the Milwaukee protocol to treat canine rabies in Equatorial Guinea
Rubin J , David D , Willoughby RE Jr , Rupprecht CE , Garcia C , Guarda DC , Zohar Z , Stamler A . Scand J Infect Dis 2009 41 (5) 372-5 In this first report of rabies in Equatorial Guinea, problems accompanying the application of the Milwaukee Protocol are described. With its apparent success, and despite a subsequent death from complications of malnutrition, we sound a note of optimism that canine as well as bat rabies may be treatable. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure